Cambridge, MA-based Seaside Therapeutics recently announced that it has raised $30 million to pursue mid-stage clinical trial development on new therapies for Fragile X Syndrome and autism. CEO Randall L. Carpenter explained that the aim of the drug is to not only help symptoms of irritability found in many autistic children, but also to improve [...]
Despite a condition affecting hundreds of thousands and being represented by pressure groups made up of highly motivated parents, very few drug companies have treatments for autism as part of their reasearch goals. XConomy.com published an interesting article enquiring into the reasons for the lack of good drugs for autism. The sheer complex range of [...]
The development of effective drugs to treat autism moved a step closer this week after possibly the biggest breakthrough in the history of research into the illness. A massive genetic study comparing the DNA of more than 12,000 individuals has apparently established conclusively a specific genetic link to autism. Researchers and autism campaigners have already [...]
Researchers at the Massachusetts Institute of Technology have pinpointed two genes related to autistic like symptoms in mice. The breakthrough brings hope that autism drugs could soon be developed that target the signaling mechanisms between the equivalent two genes in the human DNA. The two genes involved are the PTEN gene, which encodes the phosphatase and [...]
